Transaction Details

Footnotes

This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. | 24,994 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. | Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. | Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November October 2, 2018 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. These options were set to expire ten years from the date of grant on October 2, 2027.